A data analysis investigated whether modifiable adverse health outcomes were prognostic factors in overall and cancer survival and incidence of second cancers in testicular cancer survivors.
Certain treatments were associated with an increased risk of death unrelated to testicular cancer.
A nurse coordinated a meeting to ensure the patient’s preferences were shared with his multidisciplinary care team.
Testicular germ cell tumor risk elevated with exposure to X-ray and CT below the waist, GI series or barium enema.
Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.
Guideline-directed care resulted in equivalent outcomes independent of hospital setting.
A subset of testicular cancer survivors experience persistent, treatment-related, long-term adverse health outcomes that affect their ability to work.
Recent research shows that although testicular cancer survivors do not totally conform to the criteria for metabolic syndrome, past treatment with platinum-based chemotherapy increases its prevalence among survivors and may lead to a greater risk for heart disease in this patient population.
Results from the ongoing Platinum Study revealed the prevalence of risk factors for CVD among survivors of testicular cancer who received chemotherapy for their cancer.
Survivors of testicular cancer are more likely to develop metabolic syndrome after platinum-based chemotherapy.
